Cargando…

Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment

This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ruxuan, Shao, Chi, Liu, Xiangning, Huang, Hui, Pan, Boju, Xu, Kai, Zhu, Rui, Li, Mei, Zhao, Yang, Chen, Keqi, Wang, Mengzhao, Xu, Zuojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885922/
https://www.ncbi.nlm.nih.gov/pubmed/36715832
http://dx.doi.org/10.1007/s10238-023-00999-1
_version_ 1784880027996782592
author Chen, Ruxuan
Shao, Chi
Liu, Xiangning
Huang, Hui
Pan, Boju
Xu, Kai
Zhu, Rui
Li, Mei
Zhao, Yang
Chen, Keqi
Wang, Mengzhao
Xu, Zuojun
author_facet Chen, Ruxuan
Shao, Chi
Liu, Xiangning
Huang, Hui
Pan, Boju
Xu, Kai
Zhu, Rui
Li, Mei
Zhao, Yang
Chen, Keqi
Wang, Mengzhao
Xu, Zuojun
author_sort Chen, Ruxuan
collection PubMed
description This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective analysis of the clinical characteristics of hospitalized LC patients with definite pathological diagnoses was performed from 2014 to 2021. ILD was defined after the review of chest CT imaging. There were 13,085 hospitalized LC patients. Among them, 509 patients (3.89%) had 551 cases of ILD. There were variable underlying causes of ILD, including idiopathic interstitial pneumonia (360 patients), LC treatment-associated ILD (134 cases), and connective tissue disease-associated ILD (55 patients). Although most LC-ILD patients were suffering from adenocarcinoma (204/40.1%), SCLC patients were prone to concomitant ILD (10.8% of all SCLC cases), followed by SCC (9.6% of all SCC cases). All but 10 LC-ILD patients received anti-LC treatment; however, only 39 (10.8%) LC-IIP patients received anti-ILD treatment. There were more LC-ILD patients in the 2018–2021 group than in the 2014–2017 group (5.16% vs. 2.03%, p < 0.001). The underlying causes of ILD were significantly different between the 2018–2021 group and the 2014–2017 group (p < 0.001). After adjusting for the number of hospitalized patients having the same LC pathological pattern, SCLC was determined to be the most likely to be concomitant with ILD, followed by SCC. Most LC-ILD patients were scheduled for anti-LC therapy; however, treatments for concomitant IIP were usually ignored. LC treatment-associated ILD should receive more attention than before.
format Online
Article
Text
id pubmed-9885922
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98859222023-01-30 Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment Chen, Ruxuan Shao, Chi Liu, Xiangning Huang, Hui Pan, Boju Xu, Kai Zhu, Rui Li, Mei Zhao, Yang Chen, Keqi Wang, Mengzhao Xu, Zuojun Clin Exp Med Research This study aimed to explore the general characteristics and spectrum of hospitalized Chinese patients suffering from lung cancer with concomitant interstitial lung disease (LC-ILD). Furthermore, we compared their features before and after the period of immunotherapy for lung cancer. A retrospective analysis of the clinical characteristics of hospitalized LC patients with definite pathological diagnoses was performed from 2014 to 2021. ILD was defined after the review of chest CT imaging. There were 13,085 hospitalized LC patients. Among them, 509 patients (3.89%) had 551 cases of ILD. There were variable underlying causes of ILD, including idiopathic interstitial pneumonia (360 patients), LC treatment-associated ILD (134 cases), and connective tissue disease-associated ILD (55 patients). Although most LC-ILD patients were suffering from adenocarcinoma (204/40.1%), SCLC patients were prone to concomitant ILD (10.8% of all SCLC cases), followed by SCC (9.6% of all SCC cases). All but 10 LC-ILD patients received anti-LC treatment; however, only 39 (10.8%) LC-IIP patients received anti-ILD treatment. There were more LC-ILD patients in the 2018–2021 group than in the 2014–2017 group (5.16% vs. 2.03%, p < 0.001). The underlying causes of ILD were significantly different between the 2018–2021 group and the 2014–2017 group (p < 0.001). After adjusting for the number of hospitalized patients having the same LC pathological pattern, SCLC was determined to be the most likely to be concomitant with ILD, followed by SCC. Most LC-ILD patients were scheduled for anti-LC therapy; however, treatments for concomitant IIP were usually ignored. LC treatment-associated ILD should receive more attention than before. Springer International Publishing 2023-01-30 2023 /pmc/articles/PMC9885922/ /pubmed/36715832 http://dx.doi.org/10.1007/s10238-023-00999-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Chen, Ruxuan
Shao, Chi
Liu, Xiangning
Huang, Hui
Pan, Boju
Xu, Kai
Zhu, Rui
Li, Mei
Zhao, Yang
Chen, Keqi
Wang, Mengzhao
Xu, Zuojun
Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title_full Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title_fullStr Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title_full_unstemmed Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title_short Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment
title_sort clinical spectrum of chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of lc treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885922/
https://www.ncbi.nlm.nih.gov/pubmed/36715832
http://dx.doi.org/10.1007/s10238-023-00999-1
work_keys_str_mv AT chenruxuan clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT shaochi clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT liuxiangning clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT huanghui clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT panboju clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT xukai clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT zhurui clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT limei clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT zhaoyang clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT chenkeqi clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT wangmengzhao clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment
AT xuzuojun clinicalspectrumofchinesehospitalizedlungcancerpatientswithconcomitantinterstitiallungdiseasebeforeandaftertheneweraoflctreatment